Literature DB >> 18832085

Selective estrogen receptor-alpha and estrogen receptor-beta agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide-dependent mechanism.

Tim Lahm1, Paul R Crisostomo, Troy A Markel, Meijing Wang, Yue Wang, Jiangning Tan, Daniel R Meldrum.   

Abstract

Both endogenous and exogenous estrogen decrease pulmonary artery (PA) vasoconstriction. Whether these effects are mediated via estrogen receptor (ER)-alpha or ER-beta, and whether the contribution of ERs is stimulus-dependent, remains unknown. We hypothesized that administration of the selective ER-alpha agonist propylpyrazole triol (PPT) and/or the selective ER-beta agonist diarylpropiolnitrile (DPN) rapidly decreases PA vasoconstriction induced by pharmacologic and hypoxic stimuli via a nitric oxide (NO)-dependent mechanism. PA rings (n = 3-10/group) from adult male Sprague-Dawley rats were suspended in physiologic organ baths. Force displacement was measured. Vasoconstrictor responses to phenylephrine (10(-8)M - 10(-5)M) and hypoxia (Po(2) 35-45 mmHg) were determined. Endothelium-dependent and -independent vasorelaxation were measured by generating dose-response curves to acetylcholine (10(-8)M - 10(-4)M) and sodium nitroprusside (10(-9)M - 10(-5)M). PPT or DPN (10(-9)M - 5 x 10(-5)M) were added to the organ bath in the presence and absence of the NO-synthase inhibitor N(omega)-nitro-l-arginine methyl ester (l-NAME) (10(-4)M). Selective ER-alpha activation (PPT, 5 x 10(-5)M) rapidly (<20 min) decreased phenylephrine-induced vasoconstriction. This effect, as well as PPT's effects on endothelium-dependent vasorelaxation, were neutralized by l-NAME. In contrast, selective ER-beta activation (DPN, 5 x 10(-5)M) rapidly decreased phase II of hypoxic pulmonary vasoconstriction (HPV). l-NAME eliminated this phenomenon. Lower PPT or DPN concentrations were less effective. We conclude that both ER-alpha and ER-beta decrease PA vasoconstriction. The immediate onset of effect suggests a nongenomic mechanism. The contribution of specific ERs appears to be stimulus specific, with ER-alpha primarily modulating phenylephrine-induced vasoconstriction, and ER-beta inhibiting HPV. NO inhibition eliminates these effects, suggesting a central role for NO in mediating the pulmonary vascular effects of both ER-alpha and ER-beta.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832085      PMCID: PMC2584849          DOI: 10.1152/ajpregu.90667.2008

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  44 in total

1.  Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase.

Authors:  T Simoncini; A Hafezi-Moghadam; D P Brazil; K Ley; W W Chin; J K Liao
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

2.  Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury.

Authors:  Gary Pare; Andrée Krust; Richard H Karas; Sonia Dupont; Mark Aronovitz; Pierre Chambon; Michael E Mendelsohn
Journal:  Circ Res       Date:  2002-05-31       Impact factor: 17.367

3.  Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries.

Authors:  K M English; R D Jones; T H Jones; A H Morice; K S Channer
Journal:  Horm Metab Res       Date:  2001-11       Impact factor: 2.936

4.  ERbeta has nongenomic action in caveolae.

Authors:  Ken L Chambliss; Ivan S Yuhanna; Richard G W Anderson; Michael E Mendelsohn; Philip W Shaul
Journal:  Mol Endocrinol       Date:  2002-05

5.  Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta.

Authors:  Yan Zhu; Zhao Bian; Ping Lu; Richard H Karas; Lin Bao; Daniel Cox; Jeffrey Hodgin; Philip W Shaul; Peter Thoren; Oliver Smithies; Jan-Ake Gustafsson; Michael E Mendelsohn
Journal:  Science       Date:  2002-01-18       Impact factor: 47.728

6.  Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells.

Authors:  K Hisamoto; M Ohmichi; H Kurachi; J Hayakawa; Y Kanda; Y Nishio; K Adachi; K Tasaka; E Miyoshi; N Fujiwara; N Taniguchi; Y Murata
Journal:  J Biol Chem       Date:  2000-10-23       Impact factor: 5.157

7.  Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues.

Authors:  M J Meyers; J Sun; K E Carlson; G A Marriner; B S Katzenellenbogen; J A Katzenellenbogen
Journal:  J Med Chem       Date:  2001-11-22       Impact factor: 7.446

8.  Gender dimorphism in neutrophil priming and activation following trauma-hemorrhagic shock.

Authors:  Balazs Toth; Martin G Schwacha; Joachim F Kuebler; Kirby I Bland; Ping Wang; Irshad H Chaudrya
Journal:  Int J Mol Med       Date:  2003-03       Impact factor: 4.101

Review 9.  Cellular and molecular pathobiology of pulmonary arterial hypertension.

Authors:  Marc Humbert; Nicholas W Morrell; Stephen L Archer; Kurt R Stenmark; Margaret R MacLean; Irene M Lang; Brian W Christman; E Kenneth Weir; Oliver Eickelberg; Norbert F Voelkel; Marlene Rabinovitch
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

10.  Dose-related effects of red wine and alcohol on hemodynamics, sympathetic nerve activity, and arterial diameter.

Authors:  Jonas Spaak; Anthony C Merlocco; George J Soleas; George Tomlinson; Beverley L Morris; Peter Picton; Catherine F Notarius; Christopher T Chan; John S Floras
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-11-30       Impact factor: 4.733

View more
  31 in total

Review 1.  Pulmonary hypertension in women.

Authors:  Meredith E Pugh; Anna R Hemnes
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-11

Review 2.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

3.  17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects.

Authors:  Tim Lahm; Marjorie Albrecht; Amanda J Fisher; Mona Selej; Neel G Patel; Jordan A Brown; Matthew J Justice; M Beth Brown; Mary Van Demark; Kevin M Trulock; Dino Dieudonne; Jagadeshwar G Reddy; Robert G Presson; Irina Petrache
Journal:  Am J Respir Crit Care Med       Date:  2012-03-01       Impact factor: 21.405

Review 4.  Sex differences in the pulmonary circulation: implications for pulmonary hypertension.

Authors:  Yvette N Martin; Christina M Pabelick
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-03-07       Impact factor: 4.733

5.  Sex and menopause differences in response to tadalafil: 6-minute walk distance and time to clinical worsening.

Authors:  Jennifer Rusiecki; Youlan Rao; Jody Cleveland; Zachary Rhinehart; Hunter C Champion; Michael A Mathier
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

Review 6.  Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease.

Authors:  Meredith E Pugh; Anna R Hemnes
Journal:  Womens Health (Lond)       Date:  2010-03

7.  The association between body mass index, lipid profile and serum estradiol levels in a sample of iraqi diabetic premenopausal women.

Authors:  Zinah Abd Ulelah Abd Ali; Mahmood Shakir Al-Zaidi
Journal:  Oman Med J       Date:  2011-07

Review 8.  Sex steroid signaling: implications for lung diseases.

Authors:  Venkatachalem Sathish; Yvette N Martin; Y S Prakash
Journal:  Pharmacol Ther       Date:  2015-01-14       Impact factor: 12.310

Review 9.  Metabolic and hormonal derangements in pulmonary hypertension: from mouse to man.

Authors:  M E Pugh; A R Hemnes
Journal:  Int J Clin Pract Suppl       Date:  2010-11

10.  Selective endothelin-A receptor blockade attenuates endotoxin-induced pulmonary hypertension and pulmonary vascular dysfunction.

Authors:  Brent M Toney; Amanda J Fisher; Marjorie Albrecht; Angelia D Lockett; Robert G Presson; Irina Petrache; Tim Lahm
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.